Today's global health is a very lucrative market, with pharmaceutical companies at the top of the food chain in terms of global revenues. Because most of you will know there are various kinds of medical disorders and clinical diseases such as cardiovascular and neurodegenerative diseases that astonish its effect on one billion people worldwide. As a result, innovative medical and pharmaceutical companies constantly engineer and create new treatments.
But the problem lies in achieving results and processes in doing so. The most common and detrimental method is clinical trials to the public, where treatment reacts differently to each subject depending on their genetics. Decrease down can include inaccurate test results, large or small side effects and long process drawn with the final result without conclusion.
Revolution
Until recently, DNA sequencing is very expensive but now more and more drugs and medical companies are greatly benefited from the study of genomic data. This data can be used to discover new ways to prevent, treat and possibly even cure thousands of various diseases and disorders. Not only can data be used for medical breakthroughs, it can be used for ancestral knowledge and to explore your family roots.
Until recently, DNA sequencing is very expensive but now more and more drugs and medical companies are greatly benefited from the study of genomic data. This data can be used to discover new ways to prevent, treat and possibly even cure thousands of various diseases and disorders. Not only can data be used for medical breakthroughs, it can be used for ancestral knowledge and to explore your family roots.
Our genome data is specifically unique to each and every one of us, therefore when this data is studied it is combined with thousands of other genetic data being cross-checked. Medical professionals such as doctors and specialists can draw better conclusions about what treatment is required for an individual who is tailor made for the best results.
Genome data and clinical data are generally still collected and studied in silos, many countries have placed strict provisions that guide international division, and some even ban it completely. Apart from these limitations, more and more genome data are generated and available from various sources. The institutions and companies involved in this division, basically selling human genome data for big profits, of course we have the right to have genome data and gain profits ...
Shivom
This is where Shivom enters, the next genomic and health care era. Shivom offers services to patients and genome data donors that combine two revolutionary technologies, blockchain and genomic data. In this way everyone can have the genome sorted and stored safely using blockchain. This unique and innovative idea also means that patients and genomic data donors have their data and access rights, they also have the option to share their genome data for profit or rewards. Patients obtain personal health, well-being, and lifestyle information and they also receive access to ancestral information such as family trees.
This is where Shivom enters, the next genomic and health care era. Shivom offers services to patients and genome data donors that combine two revolutionary technologies, blockchain and genomic data. In this way everyone can have the genome sorted and stored safely using blockchain. This unique and innovative idea also means that patients and genomic data donors have their data and access rights, they also have the option to share their genome data for profit or rewards. Patients obtain personal health, well-being, and lifestyle information and they also receive access to ancestral information such as family trees.
An important part that blockchain plays is keeping the patient's genome data safe and secure. A public key is created for each patient which can then be encrypted and then shared if selected, the patient has the right to access and to whom they choose to share it. Blockchain also makes it easier to share information with stakeholders or in other cases make certain stakeholders unable to access the info. it's all getting better ... medical and pharmaceutical companies will use the Shivom platform to improve drug development. By accessing information shared by genomic data donors, companies will be able to achieve more accurate results in a more efficient, beneficial way to patients and ecosystems.
A more dynamic ecosystem is created and constantly perfected, whereby the health and pharmaceutical community can identify and remove potential health barriers before they become serious. Genomic sequencing provides many benefits:
• Identify the best care for patients with certain conditions
• Prevention of disease in healthy individuals
• Predicted disease risk
• Diagnosis of the disease
• Treatment, including the most effective drug and dose options
• Prognosis of the disease
• Identify new drug target
• Identify the best care for patients with certain conditions
• Prevention of disease in healthy individuals
• Predicted disease risk
• Diagnosis of the disease
• Treatment, including the most effective drug and dose options
• Prognosis of the disease
• Identify new drug target
Companies and third-party providers will have the option to advertise their health / fitness services and applications through Shivom.
TOTAL TOPLINE
Global health market USD $ 8.7 trillion by 2020
Deloitte 2017 global health sector prospect
Precision drug market CAGR 14.9% (2017-2025) USD $ 40 billion by the end of 2016 CAGR 10-11% in 2025 - is expected to reach up to 112.6 billion. These include large data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnosis, and more.
Precision Market Analysis & Trend - Therapeutics, Applications- Forecast until 2025
Global health market USD $ 8.7 trillion by 2020
Deloitte 2017 global health sector prospect
Precision drug market CAGR 14.9% (2017-2025) USD $ 40 billion by the end of 2016 CAGR 10-11% in 2025 - is expected to reach up to 112.6 billion. These include large data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnosis, and more.
Precision Market Analysis & Trend - Therapeutics, Applications- Forecast until 2025
Token
Token OmiX allows purchase, trade and other services. Tokens are fuels from the Shivom ecosystem, as well as parts of system governance. There are many benefits of OmiX tokens that include premium services in the Shivom ecosystem, genome sequencing kits, sponsoring access sequence projects to health / fitness applications from 3rd party providers, access to genomic databases and use of tokens to pay donors for data / participation in studies research. Which makes it advantageous for both parties on both sides of the fence.
Token OmiX allows purchase, trade and other services. Tokens are fuels from the Shivom ecosystem, as well as parts of system governance. There are many benefits of OmiX tokens that include premium services in the Shivom ecosystem, genome sequencing kits, sponsoring access sequence projects to health / fitness applications from 3rd party providers, access to genomic databases and use of tokens to pay donors for data / participation in studies research. Which makes it advantageous for both parties on both sides of the fence.
Shivom Token Distribution will distribute 3 billion OmiX tokens
Token Sale
990M Token OmiX will be sold during the ICO process.
990M Token OmiX will be sold during the ICO process.
The
90M Token OmiX Community will be distributed to communities to grow and maintain the Shivom ecosystem, for rewards programs to enhance network effects, and for community initiatives to reward developers, entrepreneurs, and strategists.
90M Token OmiX Community will be distributed to communities to grow and maintain the Shivom ecosystem, for rewards programs to enhance network effects, and for community initiatives to reward developers, entrepreneurs, and strategists.
Founder
420M OmiX will be allocated for the founders to support the development of Shivom ecosystems and their long-term alignment with the project sustainable.
420M OmiX will be allocated for the founders to support the development of Shivom ecosystems and their long-term alignment with the project sustainable.
The
OmiX 300M Advisor will be allocated to initial support and a global network of advisors.
OmiX 300M Advisor will be allocated to initial support and a global network of advisors.
Incentivizing Growth Pool
600M OmiX will be secured in a smart contract, allocated to the database, and put into circulation in return for generating data.
600M OmiX will be secured in a smart contract, allocated to the database, and put into circulation in return for generating data.
The
OmiX 600M Reserve Company will be kept by the Foundation as a reserve fund for future data contributions, running the Foundation and unprofitable R & D efforts. The Foundation maintains all authorities to utilize some or some of the backup tokens for future external investors.
OmiX 600M Reserve Company will be kept by the Foundation as a reserve fund for future data contributions, running the Foundation and unprofitable R & D efforts. The Foundation maintains all authorities to utilize some or some of the backup tokens for future external investors.
Project Shivom has started their ICO for OMIX tokens
WHEN - Beginning March 26, 2018 and will last for 4 weeks or until hardcap is achieved
WHEN - Beginning March 26, 2018 and will last for 4 weeks or until hardcap is achieved
HARD CAP - 420,000 ETH
TOTAL TOKEN SUPPLY - 3.000.000.000
SALES PRICE IN TOKEN - 0.00014 ETH
PLATFORM - Ethereum
ACCEPT - ETH
Join ICO
ANN / Bounty Threads
Shivom Telegram
Shivom website - https://shivom.io/
ANN / Bounty threads - https://bitcointalk.org/index.php?topic=3183600.0
Telegram Shivom - https://t.me/projshivom
Shivom facebook - https://www.facebook.com/ProjectShivom/
Shivom twitter - https://twitter.com/projectshivom?lang=en
author: Putriarka.
Komentar
Posting Komentar